BridgeBio Pharma (BBIO) Other Accumulated Expenses (2018 - 2026)

BridgeBio Pharma has reported Other Accumulated Expenses for 9 years, with the latest figure at $135.5 million in Q1 2026.

• Quarterly Other Accumulated Expenses rose 991.23% year-over-year to $135.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $135.5 million (up 991.23% YoY) and the FY2025 annual result came in at $120.2 million, up 263.53% from the prior year.
• Other Accumulated Expenses climbed to $135.5 million in Q1 2026 per BBIO's latest filing, from $120.2 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $135.5 million in Q1 2026 and troughed at $4.7 million in Q4 2023.
• A 5-year average of $38.2 million and a median of $23.0 million in 2022 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2026: Other Accumulated Expenses plunged 82.86% in 2022, then soared 991.23% in 2026.
• Over 5 years, Other Accumulated Expenses stood at $5.2 million in 2022, then fell by 10.27% to $4.7 million in 2023, then soared by 610.14% to $33.1 million in 2024, then soared by 263.53% to $120.2 million in 2025, then rose by 12.72% to $135.5 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $135.5 million, $120.2 million, and $92.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.